Ticker Details
Exelixis, Inc. Common Stock Exelixis Inc is a biotechnology company. It is involved in discovery, development, and commercialization of new medicines for people with cancer. The Cabometyx product generates maximum revenue for the company.
IPO Date:	May 1, 2000
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$11.33B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.26 | 2.18%
Avg Daily Range (30 D):	$0.57 | 1.31%
Avg Daily Range (90 D):	$0.64 | 1.51%

Institutional Daily Volume
Avg Daily Volume:	2.07M
Avg Daily Volume (30 D):	2.13M
Avg Daily Volume (90 D):	2.2M

Trade Size
Avg Trade Size (Sh.):	155
Avg Trade Size (Sh.) (30 D):	63
Avg Trade Size (Sh.) (90 D):	61

Institutional Trades
Total Institutional Trades:	12,470
Avg Institutional Trade:	$3M
Avg Institutional Trade (30 D):	$5.07M
Avg Institutional Trade (90 D):	$4.97M
Avg Institutional Trade Volume:	.16M
Avg Institutional Trades (Per Day):	3

Market Closing Trades
Avg Closing Trade:	$7.26M
Avg Closing Trade (30 D):	$19.53M
Avg Closing Trade (90 D):	$19.01M
Avg Closing Volume:	333.26K

News

Jan 15, 2026 @ 11:44 AM InSilico Lands Drug Discovery Deal After Hong Kong... Source: Bamboo Works

Jan 8, 2026 @ 10:15 AM 2 Healthcare Stocks to Buy for 2026 and Beyond Source: Prosper Junior Bakiny

Dec 2, 2025 @ 1:06 AM 2 Under-the-Radar Stocks to Buy Heading Into 2026 Source: Prosper Junior Bakiny

Oct 31, 2025 @ 11:00 AM Adagene Announces First Patient Dosed in Randomize... Source: Adagene Inc.

Oct 28, 2025 @ 5:40 PM Merck's New Cancer Therapy Combo Shows Significant... Source: Vandana Singh

Financials
	TTM	Q3 2026	Q2 2026
Basic EPS		$.72	$.68
Diluted EPS		$.69	$.65
Revenue		$597.76M	$568.26M
Gross Profit		$579.18M	$548.79M
Net Income / Loss		$193.58M	$184.85M
Operating Income / Loss		$236.54M	$213.58M
Cost of Revenue		$18.57M	$19.47M
Net Cash Flow		$211.87M	$-19.32M
PE Ratio